Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
0.249
+0.005 (2.05%)
At close: Jan 21, 2025, 4:00 PM
0.250
+0.001 (0.44%)
After-hours: Jan 21, 2025, 6:59 PM EST
Cellectar Biosciences Employees
Cellectar Biosciences had 20 employees as of December 31, 2023. The number of employees increased by 5 or 33.33% compared to the previous year.
Employees
20
Change (1Y)
5
Growth (1Y)
33.33%
Revenue / Employee
n/a
Profits / Employee
-$2,505,360
Market Cap
10.26M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
CLRB News
- 9 days ago - Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options - Benzinga
- 6 weeks ago - Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring - GlobeNewsWire
- 2 months ago - NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225) - Business Wire
- 2 months ago - Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update - GlobeNewsWire
- 2 months ago - Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 - GlobeNewsWire
- 2 months ago - Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer - GlobeNewsWire